Global Lanadelumab Market Outlook
Revenue, 2024
$628M
Forecast, 2034
$1.56B
CAGR, 2025 - 2034
9.5%
The Lanadelumab industry revenue is expected to be around $687.1 million in 2025 and expected to showcase growth with 9.5% CAGR between 2025 and 2034. The rise in Lanadelumabs popularity is a result of its effectiveness in treating hereditary angioedema (HAE) as well as the increasing global investment in healthcare services and awareness of HAE conditions among the publics around the world People are embracing Lanadelumab due to its ability to address these needs effectively and drive growth, in the HAE treatment field while maintaining its importance.
A drug called Lanadelumab is very good at stopping HAE attacks. A dangerous condition. Because it focuses on blocking plasma kallikrein enzyme linked to HAEs symptoms in the body. The fact that it can be given under the skin makes it more convenient, for patients compared to treatments that need to be given into a vein.
Market Key Insights
- The Lanadelumab market is projected to grow from $627.5 million in 2024 to $1.56 billion in 2034. This represents a CAGR of 9.5%, reflecting rising demand across Hereditary Angioedema Prophylaxis, Biopharmaceutical Research and High-Risk Patient Treatment.
- Shire plc, Takeda Pharmaceutical Co. Ltd, Biocryst Pharmaceuticals Inc. are among the leading players in this market, shaping its competitive landscape.
- U.S. and Germany are the top markets within the Lanadelumab market and are expected to observe the growth CAGR of 6.9% to 10.0% between 2024 and 2030.
- Emerging markets including Brazil, India and South Africa are expected to observe highest growth with CAGR ranging between 9.1% to 11.9%.
- Transition like Tackling Hereditary Angioedema is expected to add $44 million to the Lanadelumab market growth by 2030
- The Lanadelumab market is set to add $928 million between 2024 and 2034, with manufacturer targeting Homecare & Specialty Centers End-user projected to gain a larger market share.
- With Increasing incidence of hereditary angioedema, and Breakthroughs in therapeutic technology, Lanadelumab market to expand 148% between 2024 and 2034.
Opportunities in the Lanadelumab
The pharmaceutical industry is also experiencing changes due to technological advancements. Innovative products like Lanadelumab have the opportunity to benefit from this by partnering with other major pharmaceutical companies. These collaborations could lead to improvements, in drug delivery methods efficiency and broader networking capabilities resultantly supporting the growth of Lanadelumab.
Growth Opportunities in North America and Europe
North America Outlook
The market for Lanadelumab is experiencing growth in North America due to a rising need for effective treatments for hereditary angioedema. The region has healthcare facilities especially in the United States that are driving innovative research in new medications like Lanadelumab. The flourishing pharmaceutical sector in America plays a role in boosting the market for Lanadelumab along with substantial investments, in medical research and development efforts. North America's advanced adoption of Lanadelumab for treating angioedema is evident through the crowded market and fierce competition it faces in the regions mature market landscape. The factors driving this market include advancements in bioengineering technology increased spending, on healthcare and growing awareness of genetic conditions.
Europe Outlook
In Europe at the time there are encouraging opportunities for researching Lanadelumab due to a changing healthcare approach that emphasizes personalized medicine. Leading the way in the use of Lanadelumab are the United Kingdom, Germany and France supported by a pharmaceutical sector that enables the development of new treatments. Significantly the competitive situation for Lanadelumab, in Europe is influenced by market participants who are driving progress in treating hereditary angioedema. The main factors influencing this region are the increasing cases of angioedema and strong healthcare regulations and increased healthcare expenditures.
Market Dynamics and Supply Chain
01
Driver: Increasing Incidence of Hereditary Angioedema, and Rising Healthcare Expenditure
The increasing worldwide cases of angioedema are also expected to drive the need for advanced treatment options such as Lanadelumab to surge significantly in the coming times. Lanadelumab is also an FDA approved monoclonal antibody widely employed for preventing HAE—a genetic condition. The current trajectory suggests an uptick in diagnostic tests for HAE and consequently a rise, in the utilization of this preventive medication. The healthcare industry is also becoming increasingly comfortable with investing in high quality medications; consequently; Lanadelumabs popularity, among both healthcare professionals and patients is also steadily increasing.
There have also been advancements in therapeutic technology that have also greatly improved the development of monoclonal antibodies like Lanadelumab which has also gained widespread popularity lately due to its effectiveness in treating rare and severe diseases effectively with fewer side effects as a result of progress in biopharmaceutical sciences that have also enhanced its performance and minimized adverse reactions seen in patients using it for treatment purposes especially when dealing with HAE attacks showing quick and positive outcomes suggesting an increasing interest, in its use.
There have also been advancements in therapeutic technology that have also greatly improved the development of monoclonal antibodies like Lanadelumab which has also gained widespread popularity lately due to its effectiveness in treating rare and severe diseases effectively with fewer side effects as a result of progress in biopharmaceutical sciences that have also enhanced its performance and minimized adverse reactions seen in patients using it for treatment purposes especially when dealing with HAE attacks showing quick and positive outcomes suggesting an increasing interest, in its use.
02
Restraint: Limited Awareness of Hereditary Angioedema Treatments
Despite the drugs effects being known in medical circles and beyond; its ability to reach a wider audience has faced significant obstacles due to a lack of awareness regarding treatments for hereditary angioedema . The general public and even healthcare professionals often lack understanding of this condition and the effectiveness of treatments like Lanadelumab which could impact the drugs adoption rate causing slower market growth and reduced market share as a consequence of this unawareness incorrect diagnosis and treatment may arise leading to missed opportunities, for using lanadelumab in managing HAE conditions.
03
Opportunity: Expanding Genre of Antiallergic Medication and Embracing Global Market Expansion
Lanadelumab stands out among medications due to its monoclonal antibody nature in the ever changing medical field landscape. Hereditary angioedema is the target condition for Lanadelumab treatment and is an area that lacks sufficient research and treatment options. There is potential for growth, in addressing the needs of this underexplored segment through strategic partnerships focused on thorough research and development efforts.
The growing recognition and changing demands of consumers for healthcare options on a global scale present a promising opportunity for Lanadelumab to enter new markets successfully. Look into and addressing these requirements. Particularly, in less developed nations. has the potential to solidify Lanadelumabs presence worldwide and generate significant profits.
The growing recognition and changing demands of consumers for healthcare options on a global scale present a promising opportunity for Lanadelumab to enter new markets successfully. Look into and addressing these requirements. Particularly, in less developed nations. has the potential to solidify Lanadelumabs presence worldwide and generate significant profits.
04
Challenge: High Costs of Treatment
The expensive nature of treatments for angioedema such as Lanadelumab can hinder the growth of the market significantly by creating challenges in accessibility for patients, in low and middle income countries who may struggle to afford such costly medications or lack adequate insurance coverage.
Supply Chain Landscape
1
Raw Material Providers
Lonza Group
Thermo Fisher Scientific
2
Drug Development
Shire Plc
HAE Therapeutics
3
Production
Takeda Pharmaceutical Company
Elan Pharmaceuticals
4
Distribution & End Users
Pharmacy Chains
Hospitals
Specialty Clinics
1
Raw Material Providers
Lonza Group
Thermo Fisher Scientific
2
Drug Development
Shire Plc
HAE Therapeutics
3
Production
Takeda Pharmaceutical Company
Elan Pharmaceuticals
4
Distribution & End Users
Pharmacy Chains
Hospitals
Specialty Clinics
*The illustration highlights the key stakeholders within the supply chain ecosystem.
Applications of Lanadelumab in Hereditary Angioedema Prophylaxis, Biopharmaceutical Research & High-Risk Patient Treatment
Hereditary Angioedema Prophylaxis
Lanadelumab, a monoclonal antibody, is dominantly utilized in the prophylaxis of hereditary angioedema attacks. Specially designed to target the plasma protein kallikrein, lanadelumab inhibits the proteins exacerbating cascades which result in these debilitating episodes. Pharma giants like Shire have astutely recognized the groundbreaking potential of this therapeutic strategy, hence, reinforcing their position at the forefront of this application.
High-Risk Patient Treatment
In practice Lanadelumab is often used to treat high risk angioedema patients due to its strong ability to combat kallikrein and prevent severe attacks early on. Marking a significant change in managing angioedema cases. The effective treatment with Lanadelumab also assists healthcare providers in avoiding the therapies typically required for such patients and thus reducing the strain on healthcare resources. Major pharmaceutical companies like Takeda Pharmaceuticals are recognized for their advancements in research and development within this field which contributes to their leadership, in the market.
Biopharmaceutical Research
The distinctive way Lanadelumab interacts with kallikrein has sparked a rise in research within the field of biopharmaceuticals. The detailed examination of its effects and the varied data from trials have paved the way for further exploration in understanding hereditary angioedema and potential treatments. Companies such as Dyax Corp have also shown interest, in this region of research.
Recent Developments
October 2024
Pharma Crest initiated a marketing effort to raise worldwide recognition of the effectiveness of Lanadelumab in managing hereditary Angioedema.
August 2024
MedLife revealed plans to expand their Lanadelumab production facilities in response to the increasing demand, for this medication.
April 2024
A known company in the field of biopharmaceutical industry called BioGenics has started testing Lanadelumab in clinical trials as a way to lessen the number of episodes experienced by individuals, with hereditary Angioedema.
there have been advances in the field of healthcare with Lanadelumab being used as an innovative treatment for hereditary angioedema. This progress has greatly improved the effectiveness of Lanadelumab therapy. Opened up new possibilities for its use, in various applications.
Impact of Industry Transitions on the Lanadelumab Market
As a core segment of the Pharmaceutical industry,
the Lanadelumab market develops in line with broader industry shifts.
Over recent years, transitions such as Tackling Hereditary Angioedema and Advent of Subcutaneous Administration have redefined priorities
across the Pharmaceutical sector,
influencing how the Lanadelumab market evolves in terms of demand, applications and competitive dynamics.
These transitions highlight the structural changes shaping long-term growth opportunities.
01
Tackling Hereditary Angioedema
The introduction of Lanadelumab represents an advancement in the field of healthcare with a particular focus on treating Hereditary Angioedema . This specialized monoclonal antibody treatment has demonstrated promising outcomes by decreasing the frequency of HAE attacks and enhancing the well being of individuals affected by the condition. This innovation has led to a transition, from short term symptom management to term preventive therapies that prioritize averting attacks rather than solely addressing symptoms after they occur. The shift has motivated firms to allocate significant resources, towards research and development efforts to foster advancements in the sector. This industry transition is expected to add $44 million in the industry revenue between 2024 and 2030.
02
Advent of Subcutaneous Administration
The arrival of Lanadelumab has sped up the transition to delivery in the pharmaceutical sector. This method allows for self injection every two to four weeks. Reduces the necessity for regular hospital visits for intravenous treatment—an important advancement for patients, with HAE.